• Shenqi Fuzheng Injection in Glioma: SRC/PI3K/AKT

  2026-09-28

  This study combined network pharmacology with cell-based assays and a mouse glioma model to investigate Shenqi Fuzheng injection (SFI). Its findings link SFI-associated reductions in glioma cell proliferation and migration to cell-cycle changes and implicate SRC/PI3K/AKT signaling, while leaving the precise molecular targets to be established.

• Lipo3K Transfection Reagent for ccRCC Studies

  2026-09-27

  Build practical gene-modulation experiments around the OTUD3–SLC7A11 pathway and sunitinib resistance in clear cell renal cell carcinoma. Lipo3K supports DNA, siRNA, and combined delivery, with low-toxicity handling that can simplify downstream collection and optimization in challenging cell models.

• Lipo3K Transfection Reagent for ccRCC Studies

  2026-09-26

  Build clearer experiments on OTUD3–SLC7A11 signaling and sunitinib resistance with a low-toxicity lipid delivery workflow. Lipo3K supports plasmid, siRNA, and co-transfection designs, with practical timing guidance for gene-expression and RNA-interference readouts.

• Belinostat (PXD101): Cancer Research Workflows

  2026-09-25

  Belinostat (PXD101) supports controlled studies of HDAC inhibition, cell-cycle effects, and cancer-cell response in bladder and prostate models. This workflow connects practical assay design to emerging HCC spliceosome research while clearly distinguishing established product data from hypotheses that need testing.

• Pexidartinib (PLX3397): CSF1R Research Guide

  2026-09-25

  Pexidartinib (PLX3397) is an orally bioavailable, ATP-competitive inhibitor used to investigate CSF1R-mediated signaling and macrophage biology. Its product-reported activity supports experimental study of tumor microenvironment macrophage modulation, but it should not be treated as a validated SPP1-specific inhibitor.

• From Spatial IL-6 Biology to JAK1/2 Experiments

  2026-09-24

  Spatial proteomics is bringing cytokine biology into tissue context. Learn how Baricitinib (LY3009104) can test JAK1/2 dependence in compartment-aware inflammation studies—without mistaking a mechanistic hypothesis for evidence of efficacy in primary sclerosing cholangitis.

• Cabozantinib (XL184) for RCC Adaptation Studies

  2026-09-24

  Use Cabozantinib to compare early kinase suppression with the signaling and motility changes that emerge during prolonged exposure in renal cell carcinoma models. This practical workflow combines phosphoproteomics, migration, and invasion readouts while distinguishing product specifications from study-specific findings and experimental recommendations.

• Bifidobacterium, FMT, and PET in HE Rats

  2026-09-23

  This study used [18F]PBR146 PET/CT to compare Bifidobacterium and fecal microbiota transplantation in rats with bile duct ligation-induced chronic hepatic encephalopathy. Global brain uptake and several behavioral and cytokine measures did not differ significantly, but regional imaging findings supported a neuroinflammation-reducing effect of Bifidobacterium that was not observed with FMT.

• Aprotinin Workflows for Protease-Controlled Research

  2026-09-23

  Aprotinin enables controlled, reversible suppression of trypsin, plasmin, and kallikrein in biochemical, inflammatory, and cardiovascular research models. This guide combines practical dosing logic, sample-handling workflows, GRO-seq-inspired quality controls, and troubleshooting strategies for more reproducible experiments.

• Localized BDNF Release in NMJ Assembly

  2026-09-22

  The reference study shows that skeletal muscle-derived BDNF is trafficked to actin-rich podosome-like structures, where calcium-dependent, spatially restricted release supports the earliest stages of neuromuscular junction assembly. Its combination of live imaging, targeted perturbations, and muscle-specific knockout experiments links BDNF localization and proteolytic processing to aneural and nerve-induced acetylcholine receptor clustering.

• BMS-777607: From MET Biology to Translational Models

  2026-09-22

  A mechanism-first guide to using BMS-777607 as a selective c-Met inhibitor across cancer metastasis models, MET-family biology, and exploratory hiPSC-derived platelet research.

• Reserpine (N1867): Practical Lab Workflow

  2026-09-21

  Reserpine (SKU N1867) provides a high-purity, characterized research reagent for controlled neurotransmitter depletion research, antihypertensive mechanism studies, and neuropharmacology workflows. This guide covers identity checks, DMSO preparation, storage, and troubleshooting while clarifying that the product is for research use only, not diagnostic, clinical, medical, or veterinary applications.

• Firefly Luciferase mRNA: Assay Workflow

  2026-09-21

  Build more interpretable transfection, gene expression, cell viability, and imaging studies with a chemically optimized bioluminescent reporter. This workflow connects practical handling of Firefly Luciferase mRNA with delivery benchmarking and translational mRNA research.

• Nutlin-3a and the Next Logic of p53 Translation

  2026-09-20

  Nutlin-3a offers a precise way to interrogate MDM2–p53 biology while opening a translational conversation about ferroptosis, migration, and treatment strategy in glioblastoma. This article connects target engagement with experimental design, model selection, and clinically relevant decision points.

• FITC Goat Anti-Mouse IgG (H+L) Antibody Guide

  2026-09-19

  This fluorescein-conjugated secondary antibody provides fluorescent detection of mouse IgG primary antibodies in immunofluorescence, microscopy, and flow cytometry workflows. It is intended for research assay development and optimization, not as a standalone reagent for detecting non-mouse immunoglobulins or as evidence of a validated clinical diagnostic procedure.

8541 records 3/570 page Previous Next 12345 下5页 Last page